Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC
Background: Cell division cycle 6 (CDC6) is a member of the AAA+ ATPase family and has chaperone-like activity. Many studies have shown that CDC6 plays an important role in cancer development and progression. Methods: Explored CDC6 mRNA and protein expression in normal human tissues and tumors using...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325000452 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542423413161984 |
|---|---|
| author | Chenxuan Li En-di Zhang Rui Yu Bo Yuan Yunxin Yang Zhong Zeng Hanfei Huang |
| author_facet | Chenxuan Li En-di Zhang Rui Yu Bo Yuan Yunxin Yang Zhong Zeng Hanfei Huang |
| author_sort | Chenxuan Li |
| collection | DOAJ |
| description | Background: Cell division cycle 6 (CDC6) is a member of the AAA+ ATPase family and has chaperone-like activity. Many studies have shown that CDC6 plays an important role in cancer development and progression. Methods: Explored CDC6 mRNA and protein expression in normal human tissues and tumors using TCGA, GTEx, and HPA. The role of CDC6 in cancer was analyzed using multiple web platforms and software, including R, cBioPortal, UALCAN, SangerBox and others. Finally, CCK-8, EdU assays and Transwell assays were used to verify the effects of CDC6 knockdown on HCC cell proliferation, migration, and invasion. Results: CDC6 expression was upregulated in most cancers and was associated with poorer prognosis. RNA methylation may play an important role in CDC6 epigenetic modification. CDC6 was significantly positively associated with CD4+ Th2 cells and MDSC in a variety of tumors. Furthermore, immunomodulatory genes are strongly associated with CDC6 expression in most tumor types. CDC6 has higher predictive value than B. Clonality and TMB, and its expression is significantly positively correlated with TMB/MSI and DNAss/RNAss, and is closely related to cell cycle events. Down-regulation of CDC6 can inhibit proliferation, migration and invasion of HCC cells. Conclusions: CDC6 is associated with the occurrence and progression of multiple cancer types by regulating the cell cycle. It holds promise as a diagnostic and prognostic biomarker for cancer, and offers potential in immunomodulatory and targeted therapies. |
| format | Article |
| id | doaj-art-11ffda8472a343169085fa6709fc3064 |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-11ffda8472a343169085fa6709fc30642025-02-04T04:10:22ZengElsevierTranslational Oncology1936-52332025-03-0153102314Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCCChenxuan Li0En-di Zhang1Rui Yu2Bo Yuan3Yunxin Yang4Zhong Zeng5Hanfei Huang6Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaOrgan Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaOrgan Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaOrgan Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaOrgan Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaCorresponding authors: Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnan, China.; Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaCorresponding authors: Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnan, China.; Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, ChinaBackground: Cell division cycle 6 (CDC6) is a member of the AAA+ ATPase family and has chaperone-like activity. Many studies have shown that CDC6 plays an important role in cancer development and progression. Methods: Explored CDC6 mRNA and protein expression in normal human tissues and tumors using TCGA, GTEx, and HPA. The role of CDC6 in cancer was analyzed using multiple web platforms and software, including R, cBioPortal, UALCAN, SangerBox and others. Finally, CCK-8, EdU assays and Transwell assays were used to verify the effects of CDC6 knockdown on HCC cell proliferation, migration, and invasion. Results: CDC6 expression was upregulated in most cancers and was associated with poorer prognosis. RNA methylation may play an important role in CDC6 epigenetic modification. CDC6 was significantly positively associated with CD4+ Th2 cells and MDSC in a variety of tumors. Furthermore, immunomodulatory genes are strongly associated with CDC6 expression in most tumor types. CDC6 has higher predictive value than B. Clonality and TMB, and its expression is significantly positively correlated with TMB/MSI and DNAss/RNAss, and is closely related to cell cycle events. Down-regulation of CDC6 can inhibit proliferation, migration and invasion of HCC cells. Conclusions: CDC6 is associated with the occurrence and progression of multiple cancer types by regulating the cell cycle. It holds promise as a diagnostic and prognostic biomarker for cancer, and offers potential in immunomodulatory and targeted therapies.http://www.sciencedirect.com/science/article/pii/S1936523325000452Pan-cancerTCGACDC6Immune infiltrationBiomarker |
| spellingShingle | Chenxuan Li En-di Zhang Rui Yu Bo Yuan Yunxin Yang Zhong Zeng Hanfei Huang Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC Translational Oncology Pan-cancer TCGA CDC6 Immune infiltration Biomarker |
| title | Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC |
| title_full | Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC |
| title_fullStr | Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC |
| title_full_unstemmed | Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC |
| title_short | Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC |
| title_sort | comprehensive multi omics analysis showed that cdc6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including hcc |
| topic | Pan-cancer TCGA CDC6 Immune infiltration Biomarker |
| url | http://www.sciencedirect.com/science/article/pii/S1936523325000452 |
| work_keys_str_mv | AT chenxuanli comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc AT endizhang comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc AT ruiyu comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc AT boyuan comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc AT yunxinyang comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc AT zhongzeng comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc AT hanfeihuang comprehensivemultiomicsanalysisshowedthatcdc6isapotentialprognosticandimmunotherapybiomarkerformultiplecancertypesincludinghcc |